利用血浆游离氨基酸作为生物标志物来检测和预测疾病风险。

Use of plasma-free amino acids as biomarkers for detecting and predicting disease risk.

机构信息

the Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, Kanagawa, Japan.

Ajinomoto Co., Inc., Tokyo, Japan.

出版信息

Nutr Rev. 2020 Dec 1;78(12 Suppl 2):79-85. doi: 10.1093/nutrit/nuaa086.

DOI:10.1093/nutrit/nuaa086

PMID:33259618

Abstract

This paper reviews developments regarding the use of plasma-free amino acid (PFAA) profiles as biomarkers for detecting and predicting disease risk. This work was initiated and first published in 2006 and was subsequently developed by Ajinomoto Co., Inc. After commercialization in 2011, PFAA-based tests were adopted in over 1500 clinics and hospitals in Japan, and numerous clinician-led studies have been performed to validate these tests. Evidence is accumulating that PFAA profiles can be used for diabetes prediction and evaluation of frailty; in particular, decreased plasma essential amino acids could contribute to the pathophysiology of severe frailty. Integration of PFAA evaluation as a biomarker and effective essential amino acid supplementation, which improves physical and mental functions in the elderly, could facilitate the development of precision nutrition, including personalized solutions. This present review provides the background for the technology as well as more recent clinical findings, and offers future possibilities regarding the implementation of precision nutrition.

摘要

本综述介绍了血浆游离氨基酸（PFAA）谱作为检测和预测疾病风险的生物标志物的研究进展。这项工作始于 2006 年，并由味之素株式会社首次发表，随后进行了进一步的开发。2011 年商业化后，基于 PFAA 的检测方法在日本的 1500 多家诊所和医院得到采用，并且进行了许多由临床医生主导的研究来验证这些检测方法。越来越多的证据表明，PFAA 谱可用于糖尿病预测和虚弱评估；特别是，血浆必需氨基酸的减少可能导致严重虚弱的病理生理学改变。将 PFAA 评估作为生物标志物与有效的必需氨基酸补充相结合，可改善老年人的身心功能，有助于精准营养的发展，包括个性化解决方案。本综述提供了该技术的背景以及最近的临床发现，并探讨了精准营养实施的未来可能性。